DBV Technologies (NASDAQ:DBVT) Shares Down 8.2% – Here’s Why

DBV Technologies S.A. (NASDAQ:DBVT)’s share price traded down 8.2% during mid-day trading on Tuesday . The company traded as low as $16.29 and last traded at $16.6360. 66,810 shares traded hands during trading, a decline of 77% from the average session volume of 292,488 shares. The stock had previously closed at $18.12.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Guggenheim reiterated a “buy” rating and set a $51.00 target price on shares of DBV Technologies in a report on Monday, May 4th. Citizens Jmp raised their target price on shares of DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Friday, May 1st. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. Finally, Wall Street Zen raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $48.50.

DBV Technologies Stock Performance

The stock’s 50-day moving average is $19.36 and its 200 day moving average is $19.72. The stock has a market capitalization of $1.01 billion, a PE ratio of -3.83 and a beta of -0.99.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Thursday, April 30th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). The company had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $1.11 million. DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. Analysts expect that DBV Technologies S.A. will post -0.47 earnings per share for the current year.

Hedge Funds Weigh In On DBV Technologies

A number of hedge funds have recently modified their holdings of the business. Perceptive Advisors LLC purchased a new position in shares of DBV Technologies during the first quarter worth approximately $20,146,000. Vivo Capital LLC grew its position in DBV Technologies by 8.4% during the 1st quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock worth $55,726,000 after purchasing an additional 205,943 shares during the last quarter. ADAR1 Capital Management LLC purchased a new position in DBV Technologies during the 1st quarter worth $21,159,000. Royal Bank of Canada grew its position in DBV Technologies by 167.1% during the 1st quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock worth $98,000 after purchasing an additional 2,928 shares during the last quarter. Finally, Elmind Capital LP purchased a new position in DBV Technologies during the 1st quarter worth $5,536,000. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.